cilastatin and mk-7655
cilastatin has been researched along with mk-7655 in 19 studies
Research
Studies (19)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 14 (73.68) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Blizzard, TA; Bodner, R; Chen, H; Fitzgerald, P; Gude, C; Ha, S; Hairston, N; Hammond, ML; Hermes, J; Imbriglio, J; Kim, S; Lu, J; Ogawa, A; Painter, RE; Park, YW; Raghoobar, S; Scapin, G; Sharma, N; Wisniewski, D; Wu, J; Young, K | 1 |
| Brown, ML; Kartsonis, NA; Lala, M; Losada, MC; Lucasti, C; McLeroth, P; Paschke, A; Pedley, A; Rizk, ML; Sandesc, D; Vasile, L; Venskutonis, D | 1 |
| Akers, W; Brown, ML; Du, J; Kartsonis, NA; Lee, YC; Mariyanovski, V; McLeroth, P; Paschke, A; Pedley, A; Sims, M | 1 |
| Bi, S; Butterton, JR; Chavez-Eng, CM; Gotfried, MH; Jumes, PA; Mangin, E; Rhee, EG; Rizk, ML; Zhang, Z; Zhao, T | 1 |
| Bhagunde, P; Carr, D; Racine, F; Rizk, ML; Wu, J; Young, K; Zhang, Z | 1 |
| Bhagunde, P; Boundy, K; Butterton, JR; Colon-Gonzalez, F; Garrett, G; Jumes, P; Lala, M; Lasseter, K; Liu, Y; Marbury, T; Rhee, EG; Rizk, ML; Wu, J; Xu, SS | 1 |
| Claeys, KC; Rybak, JM; Smith, JR | 1 |
| Dulku, A; El Nekidy, WS; Ghazi, IM; Li, P; Patel, K; Patel, R; Sood, A | 1 |
| Asay, R; Awad, M; El Nekidy, WS; Fimognari, P; Ghazi, IM; Knarr, A | 1 |
| Boucher, HW; Brown, ML; Butterton, JR; Chen, LF; David-Wang, A; Du, J; Kartsonis, NA; Kaye, KS; Losada, MC; Paschke, A; Patel, M; Rizk, ML; Rodríguez Gonzalez, D; Roquilly, A; Tipping, R; Titov, I; Wunderink, RG; Young, K | 1 |
| Kuiper, SG; Leegwater, E; van Nieuwkoop, C; Wilms, EB | 1 |
| Hussar, DA | 1 |
| Aoyama, N; Bando, H; Brown, M; Kawahara, K; Kikukawa, H; Kohno, S; Paschke, A; Shirakawa, M; Takase, A; Yoneyama, F | 1 |
| Boundy, KE; Colon-Gonzalez, F; Li, H; Liu, N; Patel, M; Wang, H; Wang, X; Wei, Y; Yan, B; Zang, Y; Zhang, S; Zhao, X | 1 |
| Chahine, EB; Karaoui, LR; Mansour, H; Ouweini, AEL | 1 |
| Bellanti, F; Copalu, W; Daryani, NM; Gheyas, F; Hilbert, DW; Kulkarni, P; Noormohamed, N; Patel, M; Rizk, ML; Young, K | 1 |
| Amadesi, S; Ambretti, S; Bartoletti, M; Bovo, F; Bussini, L; Gaibani, P; Lazzarotto, T; Viale, P | 1 |
| Alarcón, T; Girón, RM; Gómez-Punter, RM; Ibáñez, A | 1 |
| Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP | 1 |
Reviews
3 review(s) available for cilastatin and mk-7655
| Article | Year |
|---|---|
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests | 2020 |
Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Imipenem; Male; Microbial Sensitivity Tests; Urinary Tract Infections | 2020 |
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Imipenem; Patient Acuity; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2022 |
Trials
6 trial(s) available for cilastatin and mk-7655
| Article | Year |
|---|---|
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Intraabdominal Infections; Male; Middle Aged; Treatment Outcome; Young Adult | 2016 |
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Prospective Studies; Pyelonephritis; Urinary Tract Infections; Young Adult | 2017 |
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Female; Healthy Volunteers; Humans; Imipenem; Lung; Male; Young Adult | 2018 |
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Topics: Adult; Aged; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Drug Combinations; Female; Humans; Imipenem; Male; Middle Aged; Organic Anion Transporters; Renal Insufficiency; Young Adult | 2020 |
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Topics: Adult; Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Hospitals; Humans; Imipenem; Piperacillin; Tazobactam; Ventilators, Mechanical | 2021 |
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Cilastatin, Imipenem Drug Combination; Humans; Imipenem; Intraabdominal Infections; Japan; Urinary Tract Infections | 2021 |
Other Studies
10 other study(ies) available for cilastatin and mk-7655
| Article | Year |
|---|---|
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Crystallography, X-Ray; Drug Combinations; Drug Discovery; Drug Resistance, Bacterial; Enzyme Inhibitors; Imipenem; Inhibitory Concentration 50; Klebsiella; Microbial Sensitivity Tests; Models, Biological; Pseudomonas; Structure-Activity Relationship | 2014 |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications.
Topics: Azabicyclo Compounds; Cilastatin; Drug Combinations; Imipenem; Nephelometry and Turbidimetry | 2020 |
Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Drug Combinations; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Imipenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2020 |
New drugs 2020, part 3.
Topics: Aminophenols; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Benzodioxoles; beta-Cyclodextrins; Cilastatin; Drug Approval; Drug Combinations; Ethinyl Estradiol; Genetic Vectors; Humans; Imipenem; Indoles; Nitroimidazoles; Pregnanolone; Pregnenediones; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Retinoids; United States; United States Food and Drug Administration | 2020 |
A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; China; Cilastatin; Drug Combinations; Humans; Imipenem | 2021 |
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Humans; Imipenem; Microbial Sensitivity Tests | 2021 |
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Hospitals; Humans; Imipenem; Pneumonia, Bacterial; Ventilators, Mechanical | 2022 |
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cilastatin; Drug Combinations; Humans; Imipenem; Klebsiella; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Topics: Anti-Bacterial Agents; Cilastatin; Critical Illness; Humans; Imipenem | 2022 |